{"id":349391,"date":"2025-08-25T17:20:22","date_gmt":"2025-08-25T17:20:22","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-crinetics-pharmaceuticals\/"},"modified":"2025-08-25T17:20:22","modified_gmt":"2025-08-25T17:20:22","slug":"how-to-buy-crinetics-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/","title":{"rendered":"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-349391","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Crinetics Pharmaceuticals (CRNX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Crinetics Pharmaceuticals (CRNX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin."},"intro":"\u0130leri biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Crinetics Pharmaceuticals, endokrin hastal\u0131k tedavisinde heyecan verici bir s\u0131n\u0131r\u0131 temsil ediyor. Geli\u015ftirilmekte olan \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler ve \u00f6nemli analist iyimserli\u011fi ile bu hisse senedi hem \u00f6nemli riskler hem de ola\u011fan\u00fcst\u00fc potansiyel \u00f6d\u00fcller sunuyor. CRNX'nin neden dikkatinizi hak etti\u011fini ve bu yenilik\u00e7i yolculu\u011fun bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Crinetics Pharmaceuticals, endokrin hastal\u0131k tedavisinde heyecan verici bir s\u0131n\u0131r\u0131 temsil ediyor. Geli\u015ftirilmekte olan \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler ve \u00f6nemli analist iyimserli\u011fi ile bu hisse senedi hem \u00f6nemli riskler hem de ola\u011fan\u00fcst\u00fc potansiyel \u00f6d\u00fcller sunuyor. CRNX'nin neden dikkatinizi hak etti\u011fini ve bu yenilik\u00e7i yolculu\u011fun bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel CRNX Hisse Durumu ve Kritik Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Crinetics Pharmaceuticals (CRNX) hisseleri <strong>30,99 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Bu fiyat, hissenin 52 haftal\u0131k 25,56 $ ile 60,69 $ aras\u0131ndaki aral\u0131\u011f\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda ilgi \u00e7ekici bir giri\u015f noktas\u0131 sunuyor.<\/p> <p><strong>Takviminize not edin: 11 Kas\u0131m 2025<\/strong> kesinlikle kritik bir tarih. Bu tarihte Crinetics bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayacak. Tarihsel olarak, bu raporlar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p> <p><strong>25 Eyl\u00fcl 2025<\/strong> ise daha da \u00f6nemli - bu tarih, akromegali i\u00e7in \u00f6nde gelen ila\u00e7 aday\u0131 paltusotine i\u00e7in FDA PDUFA hedef i\u015flem tarihidir. Bu ikili olay, \u015firketin de\u011ferlemesini bir gecede dramatik \u015fekilde de\u011fi\u015ftirebilir.<\/p> <h3>FDA Kararlar\u0131n\u0131n CRNX Hisselerine Etkisi<\/h3> <p>Son d\u00fczenleyici tetikleyicilere bakmak de\u011ferli i\u00e7g\u00f6r\u00fcler sa\u011flar:<\/p> <ul> <li><strong>21 A\u011fustos 2025<\/strong>: FDA, atumelnant i\u00e7in Yetim \u0130la\u00e7 Tasar\u0131m\u0131 verdi - hisse orta d\u00fczeyde pozitif tepki verdi<\/li> <li><strong>9 Aral\u0131k 2024<\/strong>: FDA, paltusotine NDA's\u0131n\u0131 kabul etti - hisse sonraki hafta %18 y\u00fckseldi<\/li> <li><strong>\u00d6nceki klinik veri a\u00e7\u0131klamalar\u0131<\/strong>: Genellikle her iki y\u00f6nde %15-25 dalgalanmalara neden olur<\/li> <\/ul> <p>Desen a\u00e7\u0131k: d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 patlay\u0131c\u0131 volatilite yarat\u0131r. Ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar bu olaylardan \u00f6nce pozisyon al\u0131rken riski uygun \u015fekilde y\u00f6netir.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Seyri ve Trend Analizi<\/h2> <p>CRNX son alt\u0131 ayda bir ini\u015f \u00e7\u0131k\u0131\u015f ya\u015fad\u0131:<\/p> <p><strong>\u015eubat 2025<\/strong>: 42,50 $ (tatil sonras\u0131 toparlanma)<br\/> <strong>Nisan 2025<\/strong>: 35,20 $ (klinik deneme belirsizli\u011fi)<br\/> <strong>Haziran 2025<\/strong>: 38,90 $ (ENDO konferans\u0131 iyimserli\u011fi)<br\/> <strong>A\u011fustos 2025<\/strong>: 30,99 $ (mevcut seviyeler)<\/p> <p>Bu, \u015eubat zirvesinden itibaren <strong>%27 d\u00fc\u015f\u00fc\u015f<\/strong> anlam\u0131na gelir ve ba\u015fl\u0131ca nedenleri \u015funlard\u0131r:<\/p> <ul> <li>Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fc zay\u0131fl\u0131\u011f\u0131<\/li> <li>\u00d6nceki kazan\u00e7lardan kar realizasyonu<\/li> <li>Tipik FDA karar\u0131 \u00f6ncesi volatilite<\/li> <\/ul> <p>Ancak, hisse 30 $ civar\u0131nda g\u00fc\u00e7l\u00fc destek bulmu\u015f g\u00f6r\u00fcn\u00fcyor, bu da bir sonraki b\u00fcy\u00fck kataliz\u00f6r \u00f6ncesi konsolidasyon a\u015famas\u0131 olabilir.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve klinik pipeline ilerlemesine dayanarak:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 45-55 $ (FDA karar\u0131 ba\u015far\u0131l\u0131 olursa) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br\/> <strong>2026<\/strong>: 65-80 $ (ticari lansman ivmesi)<br\/> <strong>2028<\/strong>: 90-120 $ (pipeline geni\u015flemesi ve pazar penetrasyonu)<br\/> <strong>2030<\/strong>: 150+ $ (yerle\u015fik endokrin tedavi lideri)<\/p> <p>Fark neredeyse tamamen 25 Eyl\u00fcl FDA karar\u0131na ba\u011fl\u0131d\u0131r. Onay, an\u0131nda %50-100 kazan\u00e7 tetikleyebilirken, reddedilme %30-50 d\u00fc\u015f\u00fc\u015fe yol a\u00e7abilir.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>FDA reddi riski<\/strong>: 25 Eyl\u00fcl'deki ikili sonu\u00e7 y\u0131k\u0131c\u0131 olabilir<\/li> <li><strong>Nakit yakma endi\u015feleri<\/strong>: 155 milyon $ negatif serbest nakit ak\u0131\u015f\u0131 dikkatli izlenmeli<\/li> <li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Birden fazla endikasyon i\u00e7in Faz 3 sonu\u00e7lar\u0131 bekleniyor<\/li> <li><strong>Rekabet<\/strong>: Novartis gibi yerle\u015fik oyuncular mevcut pazar\u0131 domine ediyor<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Yetim ila\u00e7 tasar\u0131m\u0131<\/strong>: A\u011fustos 2025'te atumelnant i\u00e7in verilen tasar\u0131m avantajlar sa\u011fl\u0131yor<\/li> <li><strong>Analist konsens\u00fcs\u00fc<\/strong>: 6 \"G\u00fc\u00e7l\u00fc Al\" derecelendirmesi ve 74 $ ortalama hedef (<a href=\"https:\/\/stockanalysis.com\/stocks\/crnx\/forecast\/\">StockAnalysis<\/a>)<\/li> <li><strong>Temiz bilan\u00e7o<\/strong>: %0 bor\u00e7\/\u00f6zsermaye oran\u0131 finansal esneklik sunuyor<\/li> <li><strong>Pazar potansiyeli<\/strong>: 1,3 milyar $ akromegali pazar\u0131 yenilik bekliyor<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>FDA sonras\u0131 d\u00fc\u015f\u00fc\u015f\u00fc bekleyin<\/strong>: Onaylan\u0131rsa, daha iyi giri\u015f i\u00e7in %10-15 geri \u00e7ekilmeyi sat\u0131n al\u0131n<\/li> <li><strong>Pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc ak\u0131ll\u0131ca ayarlay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5'inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li> <li><strong>Zarar durdurma emirleri koyun<\/strong>: K\u00f6t\u00fc FDA reddi senaryolar\u0131na kar\u015f\u0131 koruma sa\u011flar<\/li> <li><strong>Hacim art\u0131\u015flar\u0131n\u0131 izleyin<\/strong>: Artan i\u015flem aktivitesi genellikle b\u00fcy\u00fck hareketlerden \u00f6nce gelir<\/li> <\/ol> <p>Esprili bir bak\u0131\u015f: \"CRNX ticareti yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir - inan\u0131lmaz heyecan verici potansiyel, ancak beklenmedik deneyimlere ve ara s\u0131ra patlamalara haz\u0131rl\u0131kl\u0131 olun!\"<\/p>  <h2>\u2705 Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Stratejileri test etmek i\u00e7in k\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"CRNX\" aramas\u0131 yap\u0131n<\/td><td>Do\u011fru sonu\u00e7lar i\u00e7in tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Limit emirleri volatilite s\u0131ras\u0131nda fazla \u00f6deme yapmay\u0131 \u00f6nler<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>\u0130\u015flem \u00f6ncesi sipari\u015f detaylar\u0131n\u0131 \u00e7ift kontrol edin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc avantajlar sunar:<\/p> <ul> <li><strong>Minimum depozito: 5 $<\/strong> - Biyoteknoloji stratejilerini \u00f6nemli risk olmadan test etmek i\u00e7in m\u00fckemmel<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - Tek belge KYC ile dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>\u00c7e\u015fitli para \u00e7ekme se\u00e7enekleri<\/strong> - Karlar\u0131n\u0131za h\u0131zl\u0131 eri\u015fim i\u00e7in birden fazla y\u00f6ntem<\/li> <li><strong>E\u011fitim kaynaklar\u0131<\/strong> - Kapsaml\u0131 piyasa analizleri ile i\u015flem yaparken \u00f6\u011frenin<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, biyoteknoloji volatilitesinde yeni ba\u015flayanlar i\u00e7in gezinmeyi \u00e7ok daha y\u00f6netilebilir k\u0131lar.<\/p>  <h2>\ud83c\udf0d 2025'te Crinetics: Endokrin Yenilik Lideri<\/h2> <p>Crinetics Pharmaceuticals, \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 olan nadir hastal\u0131klara odaklanarak endokrin bozukluk tedavisinde \u00f6nc\u00fc konumdad\u0131r. \u015eirketin pipeline'\u0131, akromegali, konjenital adrenal hiperplazi ve ilgili durumlar i\u00e7in hasta bak\u0131m\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilecek devrim niteli\u011finde oral tedaviler i\u00e7erir.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Crinetics ara\u015ft\u0131rma ekibi, \u00f6nde gelen bile\u015fiklerinin molek\u00fcler yap\u0131s\u0131n\u0131n mercan resifi ekosistemlerinde bulunan desenlerden ilham ald\u0131\u011f\u0131n\u0131 ke\u015ffetti - do\u011fan\u0131n kimyas\u0131 modern t\u0131bb\u0131 \u015fekillendiriyor!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel CRNX Hisse Durumu ve Kritik Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Crinetics Pharmaceuticals (CRNX) hisseleri <strong>30,99 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Bu fiyat, hissenin 52 haftal\u0131k 25,56 $ ile 60,69 $ aras\u0131ndaki aral\u0131\u011f\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda ilgi \u00e7ekici bir giri\u015f noktas\u0131 sunuyor.<\/p>\n<p><strong>Takviminize not edin: 11 Kas\u0131m 2025<\/strong> kesinlikle kritik bir tarih. Bu tarihte Crinetics bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayacak. Tarihsel olarak, bu raporlar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p>\n<p><strong>25 Eyl\u00fcl 2025<\/strong> ise daha da \u00f6nemli &#8211; bu tarih, akromegali i\u00e7in \u00f6nde gelen ila\u00e7 aday\u0131 paltusotine i\u00e7in FDA PDUFA hedef i\u015flem tarihidir. Bu ikili olay, \u015firketin de\u011ferlemesini bir gecede dramatik \u015fekilde de\u011fi\u015ftirebilir.<\/p>\n<h3>FDA Kararlar\u0131n\u0131n CRNX Hisselerine Etkisi<\/h3>\n<p>Son d\u00fczenleyici tetikleyicilere bakmak de\u011ferli i\u00e7g\u00f6r\u00fcler sa\u011flar:<\/p>\n<ul>\n<li><strong>21 A\u011fustos 2025<\/strong>: FDA, atumelnant i\u00e7in Yetim \u0130la\u00e7 Tasar\u0131m\u0131 verdi &#8211; hisse orta d\u00fczeyde pozitif tepki verdi<\/li>\n<li><strong>9 Aral\u0131k 2024<\/strong>: FDA, paltusotine NDA&#8217;s\u0131n\u0131 kabul etti &#8211; hisse sonraki hafta %18 y\u00fckseldi<\/li>\n<li><strong>\u00d6nceki klinik veri a\u00e7\u0131klamalar\u0131<\/strong>: Genellikle her iki y\u00f6nde %15-25 dalgalanmalara neden olur<\/li>\n<\/ul>\n<p>Desen a\u00e7\u0131k: d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 patlay\u0131c\u0131 volatilite yarat\u0131r. Ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar bu olaylardan \u00f6nce pozisyon al\u0131rken riski uygun \u015fekilde y\u00f6netir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Seyri ve Trend Analizi<\/h2>\n<p>CRNX son alt\u0131 ayda bir ini\u015f \u00e7\u0131k\u0131\u015f ya\u015fad\u0131:<\/p>\n<p><strong>\u015eubat 2025<\/strong>: 42,50 $ (tatil sonras\u0131 toparlanma)<br \/> <strong>Nisan 2025<\/strong>: 35,20 $ (klinik deneme belirsizli\u011fi)<br \/> <strong>Haziran 2025<\/strong>: 38,90 $ (ENDO konferans\u0131 iyimserli\u011fi)<br \/> <strong>A\u011fustos 2025<\/strong>: 30,99 $ (mevcut seviyeler)<\/p>\n<p>Bu, \u015eubat zirvesinden itibaren <strong>%27 d\u00fc\u015f\u00fc\u015f<\/strong> anlam\u0131na gelir ve ba\u015fl\u0131ca nedenleri \u015funlard\u0131r:<\/p>\n<ul>\n<li>Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fc zay\u0131fl\u0131\u011f\u0131<\/li>\n<li>\u00d6nceki kazan\u00e7lardan kar realizasyonu<\/li>\n<li>Tipik FDA karar\u0131 \u00f6ncesi volatilite<\/li>\n<\/ul>\n<p>Ancak, hisse 30 $ civar\u0131nda g\u00fc\u00e7l\u00fc destek bulmu\u015f g\u00f6r\u00fcn\u00fcyor, bu da bir sonraki b\u00fcy\u00fck kataliz\u00f6r \u00f6ncesi konsolidasyon a\u015famas\u0131 olabilir.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve klinik pipeline ilerlemesine dayanarak:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 45-55 $ (FDA karar\u0131 ba\u015far\u0131l\u0131 olursa) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br \/> <strong>2026<\/strong>: 65-80 $ (ticari lansman ivmesi)<br \/> <strong>2028<\/strong>: 90-120 $ (pipeline geni\u015flemesi ve pazar penetrasyonu)<br \/> <strong>2030<\/strong>: 150+ $ (yerle\u015fik endokrin tedavi lideri)<\/p>\n<p>Fark neredeyse tamamen 25 Eyl\u00fcl FDA karar\u0131na ba\u011fl\u0131d\u0131r. Onay, an\u0131nda %50-100 kazan\u00e7 tetikleyebilirken, reddedilme %30-50 d\u00fc\u015f\u00fc\u015fe yol a\u00e7abilir.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>FDA reddi riski<\/strong>: 25 Eyl\u00fcl&#8217;deki ikili sonu\u00e7 y\u0131k\u0131c\u0131 olabilir<\/li>\n<li><strong>Nakit yakma endi\u015feleri<\/strong>: 155 milyon $ negatif serbest nakit ak\u0131\u015f\u0131 dikkatli izlenmeli<\/li>\n<li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Birden fazla endikasyon i\u00e7in Faz 3 sonu\u00e7lar\u0131 bekleniyor<\/li>\n<li><strong>Rekabet<\/strong>: Novartis gibi yerle\u015fik oyuncular mevcut pazar\u0131 domine ediyor<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Yetim ila\u00e7 tasar\u0131m\u0131<\/strong>: A\u011fustos 2025&#8217;te atumelnant i\u00e7in verilen tasar\u0131m avantajlar sa\u011fl\u0131yor<\/li>\n<li><strong>Analist konsens\u00fcs\u00fc<\/strong>: 6 &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecelendirmesi ve 74 $ ortalama hedef (<a href=\"https:\/\/stockanalysis.com\/stocks\/crnx\/forecast\/\">StockAnalysis<\/a>)<\/li>\n<li><strong>Temiz bilan\u00e7o<\/strong>: %0 bor\u00e7\/\u00f6zsermaye oran\u0131 finansal esneklik sunuyor<\/li>\n<li><strong>Pazar potansiyeli<\/strong>: 1,3 milyar $ akromegali pazar\u0131 yenilik bekliyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>FDA sonras\u0131 d\u00fc\u015f\u00fc\u015f\u00fc bekleyin<\/strong>: Onaylan\u0131rsa, daha iyi giri\u015f i\u00e7in %10-15 geri \u00e7ekilmeyi sat\u0131n al\u0131n<\/li>\n<li><strong>Pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc ak\u0131ll\u0131ca ayarlay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5&#8217;inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li>\n<li><strong>Zarar durdurma emirleri koyun<\/strong>: K\u00f6t\u00fc FDA reddi senaryolar\u0131na kar\u015f\u0131 koruma sa\u011flar<\/li>\n<li><strong>Hacim art\u0131\u015flar\u0131n\u0131 izleyin<\/strong>: Artan i\u015flem aktivitesi genellikle b\u00fcy\u00fck hareketlerden \u00f6nce gelir<\/li>\n<\/ol>\n<p>Esprili bir bak\u0131\u015f: &#8220;CRNX ticareti yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir &#8211; inan\u0131lmaz heyecan verici potansiyel, ancak beklenmedik deneyimlere ve ara s\u0131ra patlamalara haz\u0131rl\u0131kl\u0131 olun!&#8221;<\/p>\n<h2>\u2705 Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Stratejileri test etmek i\u00e7in k\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;CRNX&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Do\u011fru sonu\u00e7lar i\u00e7in tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Limit emirleri volatilite s\u0131ras\u0131nda fazla \u00f6deme yapmay\u0131 \u00f6nler<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>\u0130\u015flem \u00f6ncesi sipari\u015f detaylar\u0131n\u0131 \u00e7ift kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito: 5 $<\/strong> &#8211; Biyoteknoloji stratejilerini \u00f6nemli risk olmadan test etmek i\u00e7in m\u00fckemmel<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; Tek belge KYC ile dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>\u00c7e\u015fitli para \u00e7ekme se\u00e7enekleri<\/strong> &#8211; Karlar\u0131n\u0131za h\u0131zl\u0131 eri\u015fim i\u00e7in birden fazla y\u00f6ntem<\/li>\n<li><strong>E\u011fitim kaynaklar\u0131<\/strong> &#8211; Kapsaml\u0131 piyasa analizleri ile i\u015flem yaparken \u00f6\u011frenin<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, biyoteknoloji volatilitesinde yeni ba\u015flayanlar i\u00e7in gezinmeyi \u00e7ok daha y\u00f6netilebilir k\u0131lar.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Crinetics: Endokrin Yenilik Lideri<\/h2>\n<p>Crinetics Pharmaceuticals, \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 olan nadir hastal\u0131klara odaklanarak endokrin bozukluk tedavisinde \u00f6nc\u00fc konumdad\u0131r. \u015eirketin pipeline&#8217;\u0131, akromegali, konjenital adrenal hiperplazi ve ilgili durumlar i\u00e7in hasta bak\u0131m\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilecek devrim niteli\u011finde oral tedaviler i\u00e7erir.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Crinetics ara\u015ft\u0131rma ekibi, \u00f6nde gelen bile\u015fiklerinin molek\u00fcler yap\u0131s\u0131n\u0131n mercan resifi ekosistemlerinde bulunan desenlerden ilham ald\u0131\u011f\u0131n\u0131 ke\u015ffetti &#8211; do\u011fan\u0131n kimyas\u0131 modern t\u0131bb\u0131 \u015fekillendiriyor!<\/p>\n"},"faq":[{"question":"Crinetics Pharmaceuticals hisseleri nereden al\u0131n\u0131r?","answer":"Crinetics Pharmaceuticals hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden CRNX sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"CRNX hissesinin riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda FDA onay\u0131n\u0131n reddedilme ihtimali, y\u00fcksek nakit yakma oran\u0131, klinik deneme sonu\u00e7lar\u0131n\u0131n belirsizli\u011fi ve g\u00fc\u00e7l\u00fc rekabet yer almaktad\u0131r."},{"question":"FDA kararlar\u0131 CRNX hisselerini nas\u0131l etkiler?","answer":"FDA kararlar\u0131 genellikle hisse fiyat\u0131nda b\u00fcy\u00fck dalgalanmalara neden olur. Onay durumunda fiyat h\u0131zla y\u00fckselirken, reddedilme durumunda \u00f6nemli d\u00fc\u015f\u00fc\u015fler ya\u015fanabilir."},{"question":"Yeni ba\u015flayanlar CRNX hissesi al\u0131rken nelere dikkat etmeli?","answer":"FDA sonras\u0131 olas\u0131 fiyat d\u00fc\u015f\u00fc\u015f\u00fcn\u00fc beklemek, portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rmak, zarar durdurma emirleri koymak ve i\u015flem hacmi art\u0131\u015flar\u0131n\u0131 takip etmek \u00f6nemlidir."},{"question":"Crinetics Pharmaceuticals'\u0131n 2025 sonras\u0131 beklentileri nelerdir?","answer":"Analistlere g\u00f6re, FDA onay\u0131 ile 2025 sonunda hisse fiyat\u0131 45-55 $ aral\u0131\u011f\u0131nda olabilir ve 2030 y\u0131l\u0131na kadar 150 $ \u00fczerinde g\u00fc\u00e7l\u00fc bir b\u00fcy\u00fcme potansiyeli bulunmaktad\u0131r."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Crinetics Pharmaceuticals hisseleri nereden al\u0131n\u0131r?","answer":"Crinetics Pharmaceuticals hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden CRNX sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"CRNX hissesinin riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda FDA onay\u0131n\u0131n reddedilme ihtimali, y\u00fcksek nakit yakma oran\u0131, klinik deneme sonu\u00e7lar\u0131n\u0131n belirsizli\u011fi ve g\u00fc\u00e7l\u00fc rekabet yer almaktad\u0131r."},{"question":"FDA kararlar\u0131 CRNX hisselerini nas\u0131l etkiler?","answer":"FDA kararlar\u0131 genellikle hisse fiyat\u0131nda b\u00fcy\u00fck dalgalanmalara neden olur. Onay durumunda fiyat h\u0131zla y\u00fckselirken, reddedilme durumunda \u00f6nemli d\u00fc\u015f\u00fc\u015fler ya\u015fanabilir."},{"question":"Yeni ba\u015flayanlar CRNX hissesi al\u0131rken nelere dikkat etmeli?","answer":"FDA sonras\u0131 olas\u0131 fiyat d\u00fc\u015f\u00fc\u015f\u00fcn\u00fc beklemek, portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rmak, zarar durdurma emirleri koymak ve i\u015flem hacmi art\u0131\u015flar\u0131n\u0131 takip etmek \u00f6nemlidir."},{"question":"Crinetics Pharmaceuticals'\u0131n 2025 sonras\u0131 beklentileri nelerdir?","answer":"Analistlere g\u00f6re, FDA onay\u0131 ile 2025 sonunda hisse fiyat\u0131 45-55 $ aral\u0131\u011f\u0131nda olabilir ve 2030 y\u0131l\u0131na kadar 150 $ \u00fczerinde g\u00fc\u00e7l\u00fc bir b\u00fcy\u00fcme potansiyeli bulunmaktad\u0131r."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T17:20:22+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T17:20:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/\",\"name\":\"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-25T17:20:22+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/","og_locale":"tr_TR","og_type":"article","og_title":"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T17:20:22+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T17:20:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/","name":"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-25T17:20:22+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Crinetics Pharmaceuticals, Inc. (CRNX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Crinetics Pharmaceuticals, Inc. (CRNX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":349392,"slug":"how-to-buy-crinetics-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Crinetics Pharmaceuticals, Inc. (CRNX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Crinetics Pharmaceuticals, Inc. (CRNX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":349389,"slug":"how-to-buy-crinetics-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Crinetics Pharmaceuticals, Inc. (CRNX) - Investimento em a\u00e7\u00f5es da Crinetics Pharmaceuticals, Inc. (CRNX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-crinetics-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/349391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=349391"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/349391\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=349391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=349391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=349391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}